MIRA Pharmaceuticals Announces Positive Toxicokinetic Results for SKNY-1

What Happened
MIRA Pharmaceuticals, Inc. filed an 8-K (Item 7.01) on August 6, 2026, and issued a press release reporting positive toxicokinetic findings from a 7‑day repeated‑dose study of its oral obesity candidate SKNY-1 in male and female Beagle dogs. The study showed rapid oral absorption, dose‑dependent systemic exposure across the tested dose range, and comparable plasma concentrations between sexes. The company said the results provide confidence in dose selection for the planned GLP toxicology program needed for IND‑enabling development.

Key Details

• Study: 7‑day repeated daily oral dosing in male and female Beagle dogs (reported August 6, 2026).
• Findings: rapid oral absorption, dose‑dependent systemic exposure, and evidence of systemic accumulation with repeated dosing.
• Sex comparison: plasma concentrations comparable between male and female animals.
• Next steps: data support dose selection for planned GLP‑compliant toxicology studies; additional preclinical efficacy and safety work still required before IND filing.

Why It Matters
These toxicokinetic results reduce uncertainty around dose selection for the company’s upcoming GLP toxicology studies, a required step toward IND‑enabling development for SKNY-1. For investors, the announcement signals progress in preclinical development and de‑risking of near‑term regulatory steps, though it does not by itself indicate clinical efficacy or guarantee regulatory approval.